185 related articles for article (PubMed ID: 21901450)
1. Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome.
Yim KL
Med Oncol; 2012 Sep; 29(3):1796-801. PubMed ID: 21901450
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
Liu J; Wang B; Fang W
Eur J Hosp Pharm; 2020 Sep; 27(5):267-270. PubMed ID: 32839257
[TBL] [Abstract][Full Text] [Related]
3. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Des Guetz G; Uzzan B; Nicolas P; Schischmanoff O; Morere JF
Target Oncol; 2009 Jan; 4(1):57-62. PubMed ID: 19343302
[TBL] [Abstract][Full Text] [Related]
7. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
Chong LC; Townsend AR; Young J; Roy A; Piantadosi C; Hardingham JE; Roder D; Karapetis C; Padbury R; Maddern G; Moore J; Price TJ
Target Oncol; 2019 Feb; 14(1):85-91. PubMed ID: 30659494
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Schischmanoff O; Perret GY; Morere JF
Anticancer Res; 2009 May; 29(5):1615-20. PubMed ID: 19443375
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Müller CI; Schulmann K; Reinacher-Schick A; Andre N; Arnold D; Tannapfel A; Arkenau H; Hahn SA; Schmoll SH; Porschen R; Schmiegel W; Graeven U;
Int J Colorectal Dis; 2008 Nov; 23(11):1033-9. PubMed ID: 18594845
[TBL] [Abstract][Full Text] [Related]
10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability in the management of colorectal cancer.
Pino MS; Chung DC
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):385-99. PubMed ID: 21651356
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.
Zaanan A; Meunier K; Sangar F; Fléjou JF; Praz F
Cell Oncol (Dordr); 2011 Jun; 34(3):155-76. PubMed ID: 21484480
[TBL] [Abstract][Full Text] [Related]
15. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Aggarwal N; Quaglia A; McPhail MJW; Monahan KJ
Int J Colorectal Dis; 2022 Jan; 37(1):35-46. PubMed ID: 34677685
[TBL] [Abstract][Full Text] [Related]
18. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.
Des Guetz G; Schischmanoff O; Nicolas P; Perret GY; Morere JF; Uzzan B
Eur J Cancer; 2009 Jul; 45(10):1890-6. PubMed ID: 19427194
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.
Copija A; Waniczek D; Witkoś A; Walkiewicz K; Nowakowska-Zajdel E
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067827
[TBL] [Abstract][Full Text] [Related]
20. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
